Authors' response to Letter to the Editor: 'Colombian experience in the management of hepatitis C'.
Schroeder S, Pedrana A, Scott N, Hellard M
The phases of hepatitis C elimination: achieving WHO elimination targets.
Pedrana A, Munari S, Stoové M, Doyle J, Hellard M
Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.
Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L, International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) Collaborative
Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.
Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J
Changes in HIV preexposure prophylaxis prescribing in Australian clinical services following COVID-19 restrictions.
Traeger MW, Patel P, Guy R, Hellard ME, Stoové MA, Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS)
COVID-19